Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +36.41%
#3 Cysic Cysic +17.50%
#4 Bedrock Bedrock +11.95%
#5 Fabric Protocol Fabric Protocol +8.04%
#6 stake.link stake.link +7.65%
#7 Cap Cap +6.89%
#8 DUSK Network DUSK Network +5.71%
#9 Pons Pons +5.51%
#10 FOLKS FOLKS +5.24%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Rank in Stocks #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Share Price
$0.051239
Last synced: 2025-11-24
Market Cap
$1.38M
Change (1 day)
-4.48%
Change (1 year)
-54.57%
Country
NO
Trade BerGenBio ASA (BGBIO)

Category

Healthcare
Revenue for BerGenBio ASA (BGBIO)
Revenue in Aug 2026 TTM: 0
According to BerGenBio ASA latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for BerGenBio ASA from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE